Dimensional Fund Advisors LP acquired a new stake in shares of Neurotrope, Inc. (NASDAQ:NTRP) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 47,443 shares of the company’s stock, valued at approximately $445,000. Dimensional Fund Advisors LP owned approximately 0.60% of Neurotrope as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of NTRP. Vanguard Group Inc. bought a new position in Neurotrope during the 2nd quarter valued at approximately $1,828,000. Oaktop Capital Management II L.P. bought a new position in Neurotrope during the 2nd quarter valued at approximately $1,095,000. Cannell Peter B & Co. Inc. increased its position in Neurotrope by 98.7% during the 2nd quarter. Cannell Peter B & Co. Inc. now owns 124,793 shares of the company’s stock valued at $1,169,000 after buying an additional 62,000 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in Neurotrope during the 2nd quarter valued at approximately $227,000. Finally, Spark Investment Management LLC bought a new position in Neurotrope during the 2nd quarter valued at approximately $214,000. 12.93% of the stock is owned by institutional investors.
Separately, ValuEngine raised Neurotrope from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
COPYRIGHT VIOLATION NOTICE: “Dimensional Fund Advisors LP Invests $445,000 in Neurotrope, Inc. (NTRP) Stock” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/12/06/dimensional-fund-advisors-lp-invests-445000-in-neurotrope-inc-ntrp-stock.html.
Neurotrope, Inc, formerly BlueFlash Communications, Inc, is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage.
Want to see what other hedge funds are holding NTRP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurotrope, Inc. (NASDAQ:NTRP).
Receive News & Ratings for Neurotrope Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope Inc. and related companies with MarketBeat.com's FREE daily email newsletter.